Opportunity Information: Apply for PAR 14 085
Apply for PAR 14 085
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.396 Cancer Biology Research.
- This funding opportunity was created on Feb 4, 2014 and posted on Feb 4, 2014.
- Applicants must submit their applications by Dec 14, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Small businesses City or township governments County governments State governments Private institutions of higher education Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts For profit organizations other than small businesses Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PAR 14-085, titled "Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (R01)," supports revision applications to existing, active NIH R01 awards rather than brand-new standalone R01 projects. The core idea is that investigators who already hold an NIH R01 can request additional support to expand the scientific scope of their currently funded project by adding one or more new Specific Aims. In practical terms, the FOA is designed for teams that have an ongoing R01 and want to build on that foundation with a targeted expansion focused on how cellular metabolism influences anti-tumor immunity and, ultimately, how metabolic interventions could make cancer immunotherapies work better.
Scientifically, the FOA centers on “metabolic reprogramming†in the context of cancer immunotherapy. It calls for research that digs into the mechanisms linking metabolism to immune function in living systems, with an emphasis on understanding the metabolic processes that enable strong anti-tumor immune responses in vivo. A major theme is the tumor microenvironment, where nutrient availability, hypoxia, acidity, and competition for metabolic substrates can reshape immune cell behavior. Applicants are expected to investigate how that metabolic landscape affects immune effector functions, such as T cell activity, persistence, cytotoxic capacity, cytokine production, and other components of productive anti-tumor immunity. The translational goal is to use these mechanistic insights to deliberately manipulate, or “reprogram,†metabolic pathways used by the tumor, the immune system, or both, in ways that improve the effectiveness, durability, or breadth of cancer immunotherapy responses.
The mechanism is an NIH Research Project Grant (R01) revision, meaning the request must be tied to an active parent R01 and must propose an expansion through new aims that are meaningfully additive to what is already funded. The FOA explicitly anticipates collaborative projects, reflecting how metabolism, immunology, and oncology often need to be integrated across disciplines. While the summary language does not list specific experimental approaches, the emphasis on mechanistic understanding and the in vivo setting implies that competitive revisions would typically include rigorous functional studies, relevant tumor models, immune profiling, and metabolic analyses that can connect pathway-level changes to measurable anti-tumor immune outcomes.
Administratively, this is a discretionary grant opportunity from the National Institutes of Health, aligned with the Cancer Biology Research program area (CFDA 93.396). There is no cost sharing or matching requirement. The opportunity was posted on February 4, 2014, with an original and current closing date of December 14, 2016, and an archive date of January 14, 2017, indicating it is no longer active but remains relevant as a historical reference for NIH priorities and for understanding how NIH framed this research area.
Eligibility is broad and includes many categories of U.S. and non-U.S. organizations, provided the applicant has an active NIH R01 award that can serve as the parent grant for the revision. Eligible applicants listed include public and private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3) organizations), small businesses and other for-profit organizations (other than small businesses are also listed as eligible), and multiple levels of government entities (state, county, city/township, special districts), as well as independent school districts and public housing authorities/Indian housing authorities. The FOA also highlights inclusion of institutions serving specific communities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American and Native American Pacific Islander Serving Institutions (AANAPISIs), along with tribal governments and tribal organizations. Foreign organizations and foreign institutions are explicitly eligible to apply, foreign components (as NIH defines them) are allowed, and non-U.S. components of U.S. organizations may participate, which reinforces that the science focus is global even though the mechanism is an NIH revision to an active R01.
For reference and administrative support, the FOA points users to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-14-085.html and provides NIH Office of Extramural Research (OER) webmaster contact information for access or linking problems (FBOWebmaster@OD.NIH.GOV).
FAQs: NIH PAR-14-085 (R01 Revision) - Research on Metabolic Reprogramming to Improve Immunotherapy
1) What is PAR-14-085?
PAR-14-085 is an NIH funding opportunity titled "Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (R01)." It supports revision applications to existing, active NIH R01 awards, rather than brand-new, standalone R01 projects.
2) Is this opportunity for new R01 applications or only for revisions?
This opportunity is specifically for revision applications tied to an active parent NIH R01. It is not intended for investigators who want to start a new R01 project from scratch.
3) What does "revision application" mean in this context?
In this FOA, a revision application means requesting additional NIH support to expand the scientific scope of an already funded R01 by adding one or more new Specific Aims that are meaningfully additive to the existing project.
4) What is the main scientific focus of this FOA?
The FOA focuses on metabolic reprogramming in the context of cancer immunotherapy. It calls for research that clarifies how cellular metabolism influences immune function in living systems and how metabolic interventions could improve the effectiveness of anti-cancer immunotherapies.
5) What does "metabolic reprogramming" refer to here?
As framed in the FOA summary, metabolic reprogramming refers to deliberately manipulating metabolic pathways used by the tumor, the immune system, or both, based on mechanistic understanding of how metabolism shapes anti-tumor immunity, with the goal of improving immunotherapy responses.
6) What types of immune outcomes are emphasized?
The FOA emphasizes immune effector functions relevant to productive anti-tumor immunity, including aspects such as T cell activity, persistence, cytotoxic capacity, cytokine production, and other functional components that contribute to effective anti-tumor immune responses.
7) How important is the tumor microenvironment to this FOA?
The tumor microenvironment is a major theme. The FOA highlights how factors like nutrient availability, hypoxia, acidity, and competition for metabolic substrates can reshape immune cell behavior and influence anti-tumor immune responses in vivo.
8) Does the FOA prioritize in vivo research?
Yes. The summary repeatedly emphasizes understanding metabolism-immune mechanisms in living systems (in vivo) and understanding the metabolic processes that enable strong anti-tumor immune responses in vivo.
9) Are collaborative projects expected or encouraged?
Yes. The FOA explicitly anticipates collaborative projects, reflecting the integrated nature of metabolism, immunology, and oncology research.
10) What NIH grant mechanism is used?
The mechanism is an NIH Research Project Grant (R01) revision. The application must be connected to an active parent R01 and must propose an expansion through new aims that add to what is already funded.
11) Can an applicant submit without an active NIH R01?
No. The opportunity is designed for investigators and organizations that already have an active NIH R01 award that can serve as the parent grant for the revision.
12) What program area is this FOA aligned with?
It is aligned with the Cancer Biology Research program area and is listed under CFDA 93.396.
13) Is cost sharing or matching required?
No. The summary states there is no cost sharing or matching requirement.
14) When was PAR-14-085 posted and when did it close?
It was posted on February 4, 2014. The original and current closing date was December 14, 2016. The archive date is January 14, 2017.
15) Is this funding opportunity still active?
No. Based on the closing and archive dates provided, it is no longer active and should be treated as a historical reference for NIH priorities and how the research area was framed.
16) Who is eligible to apply?
Eligibility is broad across many organization types, as long as the applicant has an active NIH R01 that can serve as the parent award. Eligible entities listed include public and private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3)), small businesses, other for-profit organizations, and multiple levels of government entities.
17) Are foreign organizations eligible?
Yes. The FOA summary states that foreign organizations and foreign institutions are explicitly eligible to apply.
18) Are foreign components allowed on an application?
Yes. The summary notes that foreign components (as NIH defines them) are allowed, and that non-U.S. components of U.S. organizations may participate.
19) Does this FOA mention institutions serving specific communities?
Yes. It highlights inclusion of organizations such as HBCUs, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and AANAPISIs, as well as tribal governments and tribal organizations.
20) What types of government entities are listed as eligible applicants?
The eligibility list includes multiple government levels and structures, including state governments, county governments, city or township governments, special district governments, as well as independent school districts and public housing authorities/Indian housing authorities.
21) What is the practical goal of the research supported by this FOA?
The practical translational goal is to use mechanistic insights about metabolism and immune function to improve the effectiveness, durability, or breadth of cancer immunotherapy responses by manipulating metabolic pathways in the tumor, immune system, or both.
22) What kinds of experimental work does the FOA imply would be relevant?
While the summary does not list specific required methods, it implies that competitive revisions would typically involve rigorous functional studies, relevant tumor models, immune profiling, and metabolic analyses that connect pathway-level changes to measurable anti-tumor immune outcomes.
23) Where can applicants find the full FOA text?
The FOA points to the full announcement at: http://grants.nih.gov/grants/guide/pa-files/PAR-14-085.html
24) Who should be contacted for access or linking problems with the FOA page?
The FOA provides an NIH Office of Extramural Research (OER) webmaster contact for access or linking problems: FBOWebmaster@OD.NIH.GOV
Browse more opportunities from the same category: Education Health
Next opportunity: Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (U01)
Previous opportunity: Hemoglobinopathies Surveillance, Health Promotion, and Laboratory Capacity Demonstration Project DD12 1206
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 085
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 085) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (U01) Apply for PAR 14 086 Funding Number: PAR 14 086 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (P01) Apply for PAR 14 087 Funding Number: PAR 14 087 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 15 005 Funding Number: RFA DA 15 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV Infection of the Central Nervous System (R01) Apply for PA 14 094 Funding Number: PA 14 094 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from Central Nervous System Reservoirs (R01) Apply for PA 14 095 Funding Number: PA 14 095 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization Apply for RFA CA 14 002 Funding Number: RFA CA 14 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| NIDA Avant Garde Award Program for HIV/AIDS and Drug Use Research (DP1) Apply for RFA DA 15 004 Funding Number: RFA DA 15 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development of Software and Analysis Methods for Biomedical Big Data in Targeted Areas of High Need (U01) Apply for RFA HG 14 020 Funding Number: RFA HG 14 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Phase Clinical Trials in Imaging and Image Guided Interventions (R21) Apply for PAR 14 013 Funding Number: PAR 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Family Centered Self Management of Chronic Conditions (R21) Apply for PA 14 113 Funding Number: PA 14 113 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Family Centered Self Management of Chronic Conditions (R01) Apply for PA 14 112 Funding Number: PA 14 112 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21) Apply for PAR 14 105 Funding Number: PAR 14 105 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03) Apply for PAR 14 104 Funding Number: PAR 14 104 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01) Apply for PAR 14 106 Funding Number: PAR 14 106 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Additional Research Training Slots for NIDA Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PAR 14 115 Funding Number: PAR 14 115 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01) Apply for PAR 14 116 Funding Number: PAR 14 116 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Accelerating Improvements in the HIV Care Continuum (R01) Apply for PA 14 132 Funding Number: PA 14 132 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34) Apply for PA 14 135 Funding Number: PA 14 135 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21) Apply for PA 14 136 Funding Number: PA 14 136 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01) Apply for PA 14 137 Funding Number: PA 14 137 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 085", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.